Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)

v3.10.0.1
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Operating expenses        
Research and development $ 586,696 $ 1,211,596 $ 2,299,267 $ 2,929,678
General and administrative 1,817,543 1,166,435 4,272,799 4,578,007
Operating loss (2,404,239) (2,378,031) (6,572,066) (7,507,685)
Other income (loss)        
Change in fair value of warrant liabilities 3,351,232 647,789 (4,287,737)
Dividend income 13,737 74,723
Foreign exchange gain (loss) (1,246) (1,098) (288) 28,043
Other expense (1,903) (2,242) (2,897) 3,837
Total other income (loss) 3,361,820 644,449 71,538 (4,255,857)
Net income (loss) 957,581 (1,733,582) (6,500,528) (11,763,542)
Unrealized gain on marketable securities 4,365 13,142
Total comprehensive income (loss) $ 961,946 $ (1,733,582) $ (6,487,386) $ (11,763,542)
Net income (loss) per share - basic $ 0.11 $ (0.28) $ (0.77) $ (1.92)
Net income (loss) per share - diluted $ 0.11 $ (0.28) $ (0.77) $ (1.92)
Weighted average number of common shares outstanding - basic 8,530,580 6,097,254 8,466,243 6,127,225
Weighted average number of common shares outstanding - diluted 8,554,320 6,097,254 8,466,243 6,127,255